scholarly journals Lymphoepithelioma-Like Carcinoma of the Bladder: A Case Report of a Rare and Particular Variant of Urothelial Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Youness Jabbour ◽  
Youssef Jabri ◽  
Hamza Lamchahab ◽  
Mohammed Tbouda ◽  
Ahmed Jahid ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
English Literature ◽  
Immunohistochemical Analysis ◽  
Lateral Wall ◽  
Large Tumor ◽  
Left Lateral Wall ◽  
Classification Of Tumors ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

Lymphoepithelioma-like carcinoma of the bladder (LELCB) is a rare variant of urothelial carcinoma first described by Zukerberg in 1991 and confirmed as a variant of urothelial carcinoma by the WHO classification of tumors of the urinary system. LELCB is characterized by a marked infiltration of lymphocytes in the area involved by the tumor which may coexist with the conventional urothelial carcinoma. LELCB are classified according to the percentage of lymphoepithelioma component within the tumor with the prognosis depending on the percentage. We report a new case of pure LELCB occurring in 63-year-old woman presenting with hematuria. Ultrasonography and cystoscopy revealed a large tumor on the left lateral wall of the bladder. Transurethral resection of the bladder tumor (TURBT) was performed. Pathological and immunohistochemical analysis revealed a high-grade muscle-invasive LELCB (G3pT2). The patient underwent an adjuvant systemic chemotherapy with no recurrence after a ten-month follow-up. To our knowledge, this is the second Moroccan case of LELCB reported in the English literature. Although its rare occurrence prognosis and ideal therapeutic management of LELCB have not been clearly established yet, literature findings encourage the adoption of a conservative approach in treatment of LELCB.

scholarly journals Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder

2018 ◽  
Vol 25 (1) ◽  
pp. 107327481880026 ◽  
Author(s):  
Akinori Minato ◽  
Hirotsugu Noguchi ◽  
Ikko Tomisaki ◽  
Atsushi Fukuda ◽  
Tatsuhiko Kubo ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Clinical Significance ◽  
Cox Regression ◽  
Squamous Differentiation ◽  
Muscle Invasive Bladder Cancer ◽  
Free Survival ◽  
Kaplan Meier ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

The prognostic value of squamous differentiation (SD) in urothelial carcinoma (UC) of the bladder is unclear. The aim of this study was to identify the clinical significance of SD in UC in terms of oncological outcomes in patients undergoing radical cystectomy (RC). We evaluated consecutive patients with muscle-invasive bladder cancer (MIBC; clinical T2-4aN0M0) treated with RC at our institution from March 2003 to March 2017. We enrolled 20 and 81 patients with UC with SD (UCSD) and pure UC, respectively. Postoperative survival outcomes were compared between the patients with UCSD and pure UC using the Kaplan-Meier method. Pre- and postcystectomy factors that influenced the overall survival (OS) and recurrence-free survival (RFS) were investigated in these patients. Multivariate Cox regression models were used to identify the predictors of OS and RFS. With a median follow-up time of 31 months, the 5-year OS rate of the UCSD and pure UC groups was 41.1% and 69.7% ( P = .002) and the 5-year RFS rate was 51.8% and 59.5% ( P = .027), respectively. The shape of the Kaplan-Meier curves for UCSD suggested a more rapid course of the disease within the first 2 years than observed in pure UC. Multivariate analyses suggested that SD in UC was significantly associated with OS (hazard ratio [HR]: 4.22; 95% confidence interval [CI]: 1.20-14.8; P = .024) and close to significance for a lower RFS (HR: 2.13, 95% CI: 0.74-6.15, P = .064). Our results indicate that SD may be an independent predictor of OS and RFS in UC of MIBC in patients undergoing RC.

Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder

Urology ◽  
2017 ◽  
Vol 100 ◽  
pp. 145-150 ◽  
Author(s):  
Thomas Golabesk ◽  
Joan Palou ◽  
Oscar Rodriguez ◽  
Ruben Parada ◽  
Sergio Skrobot ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Upper Urinary Tract ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

MP65-11 MUCIN 16 IS A MUTATIONAL HOTSPOT FOR NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Sumeet Syan-Bhanvadia ◽  
Christopher Duymich ◽  
Yong June Kim ◽  
Jessica Charlet ◽  
Hung-Yoon Yoon ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

scholarly journals Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1472
Author(s):  
Maria Malvina Tsamouri ◽  
Thomas M. Steele ◽  
Maria Mudryj ◽  
Michael S. Kent ◽  
Paramita M. Ghosh
Keyword(s):  
Urothelial Carcinoma ◽  
Human Cancer ◽  
Clinical Signs ◽  
Common Type ◽  
Diagnostic Biomarkers ◽  
Naturally Occurring ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive ◽  
Cancer Cell Signaling

Muscle-invasive urothelial carcinoma (MIUC) is the most common type of bladder malignancy in humans, but also in dogs that represent a naturally occurring model for this disease. Dogs are immunocompetent animals that share risk factors, pathophysiological features, clinical signs and response to chemotherapeutics with human cancer patients. This review summarizes the fundamental pathways for canine MIUC initiation, progression, and metastasis, emerging therapeutic targets and mechanisms of drug resistance, and proposes new opportunities for potential prognostic and diagnostic biomarkers and therapeutics. Identifying similarities and differences between cancer signaling in dogs and humans is of utmost importance for the efficient translation of in vitro research to successful clinical trials for both species.

scholarly journals Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system

2018 ◽  
Vol 12 (8) ◽  
Author(s):  
Adam Kinnaird ◽  
Peter Dromparis ◽  
Howard Evans
Keyword(s):  
Urothelial Carcinoma ◽  
Healthcare System ◽  
Bladder Tumour ◽  
Muscularis Propria ◽  
High Grade ◽  
Recurrence Rates ◽  
Repeat Resection ◽  
Resource Limited ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

Introduction: Non-muscle-invasive bladder cancer is the most expensive malignancy to treat. Current Canadian guidelines recommend repeat transurethral resection of bladder tumour (TURBT) within six weeks after initial resection of T1 high-grade (T1HG) urothelial carcinoma, prior to initiation of intravesical bacillus Calmette- Guerin treatment. This is a burden on operating room usage and adds further cost and risk of complications. Internationally, major cancer centres report significant rates of recurrence and upstaging on repeat resection, however, minimal Canadian data is available. We aimed to determine the rate of recurrence and upstaging in a resource-limited, Canadian healthcare system.Methods: A retrospective review of patients receiving TURBT between November 2009 and November 2014 was performed. Patients were included if they had all three of the following: a pathological diagnosis of T1HG, adequate muscularis propria present in the specimen, and a repeat resection.Results: We reviewed 3166 patients who underwent TURBT and found 173 to meet our inclusion criteria. The overall recurrence and upstaging rates were 57.2% and 9.2%, respectively. Tumour recurrence and upstaging occurred more often in patients who had repeat resection after 12‒24 weeks compared to those patients whose repeat resection occurred within 12 weeks.Conclusions: Although recurrence rates are similar, we have found upstaging rates to be three- to four-fold lower than those previously reported. Despite this, one in 10 patients will be upstaged, justifying use of this resource within our healthcare system. Finally, timely repeat resection, within 12 weeks appears to be associated with preventing disease progression.

Sign in / Sign up

Export Citation Format

Share Document